Loading
companiesCompany
BeBetter Med
BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry.
Also called: BeBetter MedicineGuangzhou BeBetter Medicine Technology
Overview
BeBetter Med, based in Guangzhou, develops small-molecule cancer drugs. Its lead programme BEBT-908 inhibits both PI3K and histone deacetylases and has been studied in relapsed or refractory diffuse large B-cell lymphoma and other lymphomas, and the company runs further trials of its pipeline in solid tumours. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Guangzhou, CN
Scorecard
All companies#298of 1244 companies, score 14
- phase 3 +6
- modalities +4
- registry trials +4
0 approved, 2 in phase 3, 0 earlier, 0 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Phase 3small molecule (structure undisclosed or not yet in PubChem)
BEBT-209 is an experimental small-molecule drug from BeBetter Med in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Ifupinostat is an experimental investigational agent whose form is not stated in the registry from BeBetter Med in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.
cancers
fronts
drugs
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
trials
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaStudy of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung CancerStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion MutationsStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy